U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Baitang Ning
  1. Science & Research (NCTR)

Baitang Ning Ph.D.

Research Biologist — Division of Bioinformatics and Biostatistics

No photo available

Baitang Ning, Ph.D.
(870) 543-7391

Back to NCTR Principal Investigators page

About  |  Publications  |  Lab Members


Dr. Baitang Ning received his Ph.D. in molecular biology and biochemistry from the University of Arkansas for Medical Sciences in 2000. He joined NCTR as a research biologist in 2002. Dr. Ning has been successful in obtaining and participating in intramurally and extramurally funded projects designed to allow investigation of problems of national/international scope that are of concern to FDA and collaborating agencies. He participated in writing the FDA Report (Blue Book) on “Paving the Way for Personalized Medicine.” Dr. Ning has received FDA Scientific Achievement Awards for his collaborations and studies. He has published 80+ articles and book chapters. In addition, he has served as an editorial board member for six journals and as a referee for 50+ journals.

Research Interests

Dr. Ning is responsible for leading a research team focusing on studies of molecular pharmacogenomics and pharmaco-epigenomics in the application of personalized medicine. He has designed, developed, and established in silico, in vivo, in vitro, and molecular pharmacological approaches to identify and evaluate genetic variations and epigenetic mechanisms for inter-individual differences in drug-metabolizing enzymes and drug-targeting enzymes. This research could help FDA reviewers better understand the inter-individual variability of drug efficacy and safety. His research activities support the FDA mission and the Critical Path initiative for personalized medicine.

National and International Groups

South Central Chapter of Society of Toxicology
2016 – 2017

Pharmacogenomics Group at the American Association of Pharmaceutical Scientists
2016 – 2017

Massive Analysis and Quality Control Society
2017 – Present


Select Publications

Publication titles are linked to text abstracts on PubMed.

Multiple MicroRNA Function as Self-Protective Modules in Acetaminophen-Induced Hepatotoxicity in Humans.
Yu D., Wu L., Gill P., Tolleson W., Chen S., Sun J., Knox B., Jin Y., Xiao W., Hong H., Wang Y., Ren Z., Guo L., Mei N., Guo Y., Yang X., Shi L., Chen Y., Zeng L., Dreval K., Tryndyak V., Pogribny I., Fang H., Shi T., Mccullough S., Bhattacharyya S., Schnackenberg L., Mattes W., Beger R., James L., Tong W., and Ning B.
Arch Toxicol. 2018, 92(2):845-858. doi: 10.1007/s00204-017-2090-y.

A Systematic Evaluation of MicroRNAs in Regulating Human Hepatic CYP2E1.
Wang Y., Yu D., Tolleson W., Yu L., Green B., Zeng L., Chen Y., Chen S., Ren Z., Guo L., Tong W., Guan H., and Ning B.
Biochem Pharmacol. 2017, 138: 174-184. doi: 10.1016/j.bcp.2017.04.020.

MicroRNA hsa-miR-25-3p Suppresses the Expression and Drug Induction of CYP2B6 in Human Hepatocytes.
Jin Y., Yu. D., Tolleson W., Green B., Wang Y., Chen S., Ren Z., Deng H., Guo Y., and Ning B.
Biochem Pharmacol. 2016, pii: S0006-2952(16)30133-2;doi:10.1016/j.bcp.2016.06.007.

Re-Annotation of Presumed Noncoding Disease/Trait-Associated Genetic Variants by Integrative Analyses.
Chen G., Yu D., Chen J., Cao R., Yang J., Wang H., Ji X., Ning B., and Shi T.
Sci Rep. 2015, 5:9453. doi: 10.1038/srep09453.

Suppression of CYP2C9 by MicroRNA hsa-mir-128-3p in Human Liver and Association with Hepatocellular Carcinoma.
Yu D., Green B., Marrone A., Guo Y., Kadlubar S., Lin D., Fuscoe J., Pogribny I., and Ning B.
Sci Rep. 2015, 5: 8534. doi: 10.1038/srep08534.

A Comprehensive Assessment of RNA-Seq Accuracy, Reproducibility and Information Content by the Sequencing Quality Control Consortium.
The SEQC/MAQC-III Consortium.
Nat. Biotechnol. 2014, doi:10.1038/nbt.2957. 

Toxicogenomics and Cancer Susceptibility: Detection by Next-Generation Sequencing.
Ning B., Su Z., Mei N., Hong H., Deng H., Shi L., Fuscoe J., and Tolleson W.
J. Environ. Sci. Health C. 2014, 32(2):121-58. doi:10.1080/10590501.2014.907460.

Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters.
Yang L., Price E., Chang C., Li Y., Huang Y., Guo L., Guo Y., Kaput J., Shi L., and Ning B.
PLoS ONE. 2013, 8(4): e60368. doi:10.1371/journal.pone.0060368.

Similarities and Differences in the Expression of Drug Metabolizing Enzymes Between Human Hepatic Cell Lines and Primary Hepatocytes.
Guo L., Dial S., Shi L., Branham W., Liu J., Fang J., Green B., Deng H., Kaput J., and Ning B.
Drug Metab Dispos. 2011, 39(3):528-38. doi:10.1124/dmd.110.035873.

The MicroArray Quality Control (MAQC)-II Study of Common Practices for the Development and Validation of Microarray-Base Predictive Models.
MAQC Consortium.
Nat Biotechnol. 2010, 228(8):827-38. Doi:10.1038/nbt.1665.

Systematic and Simultaneous Gene Profiling of 84 Drug-Metabolizing Genes in Primary Human Hepatocytes.
Ning B., Dial S., Sun Y., Wang J., and Guo L.
J. Biomol. Screen. 2008, 13(3):194-201.

A Variant of the Cockayne Syndrome B Gene ERCC6 Confers Risk of Lung Cancer.
Lin Z., Zhang Z., Tuo J., Guo Y., Green B., Chan C., Tan W., Huang Y., Ling W., Kadlubar F., Lin D., and Ning B.
Hum. Mut. 2007, doi: 10.1002/humu.20610.

Synergic Effect of Polymorphisms in ERCC6 5' Flanking Region and Complement Factor H on Age-Related Macular Degeneration Predisposition.
Tuo J., Ning B., Bojanowski C., Lin Z., Reed G., Shen D., Jiao X., Chew E., Kadlubar F., and Chan C.
Proceed. Nat. Acad. Sci. 2006, 103:9256-9261.

Common Genetic Polymorphisms in the 5’-Flanking Region of the SULT1A1 Gene: Association of Haplotypes and Platelet Enzymatic Activity.
Ning B., Nowell S., Sweeney C., Ambrosone C., Williams S., Miao X., Liang G., Lin D., Stone A., Ratnasinghe D., Manjanatha M., Lang N., and Kadlubar F.
Pharmacogenet Genomics. 2005,15(7):465-473.

Human Glutathione S-transferase A2 Polymorphisms: Variant Expression, Distribution in Prostate Cancer Cases/Controls and a Novel Form.
Ning B., Wang C., Morel F., Nowell S., Ratnasinghe D., Carter W., Kadlubar F., and Coles B.
Pharmacogenetics. 2004, 14: 35-44.

Increased Transcriptional Activity of the CYP3A4*1B Promoter Variant.
Amirimani B., Ning B., Deitz A., Weber B., Kadlubar F., and Rebbeck T.
Environ. Mol. Mutagen. 2005, 42:299-305. 


Lab Members

Contact information for all lab members:
(870) 543-7391

Bridgette Knox, B.S

Dongying Li, Ph.D.
Postdoctoral Fellow


Contact Information
Baitang Ning
(870) 543-7391
Technology & Discipline
Back to Top